Background & Aims: Interferon-free direct-acting antiviral (DAA) therapies are effective in patients with hepatitis C virus-induced cryoglobulinemia vasculitis (HCV-CV). We analyzed blood samples from patients with HCV-CV before and after DAA therapy to determine mechanisms of these drugs and their effects on cellular immunity.
Introduction
Circulating mixed cryoglobulins (MC) are detected in 40%-60% of patients with chronic hepatitis C virus (HCV) infection, whereas overt cryoglobulinemia vasculitis (CV) is observed in only 5%-10% of cases [1] [2] [3] [4] . It involves the activation of B cells, which generates pathogenic immunoglobulin (Ig) M and IgG with rheumatoid factor activity 5, 6 .
CV leads to clinical manifestations ranging from purpura, arthralgia and fatigue to more serious lesions with neurologic and renal involvement 2 . Despite success with combination antiviral treatment with or without immunosuppressive drugs, HCV-CV remains a serious disease with an estimated 5-year survival rate of 75% 4, 7 .
Treatment of HCV-CV remains difficult and requires targeting the downstream B cell arm of autoimmunity and the viral trigger to obtain clinical resolution of symptoms 8, 9 .
Two prospective randomized controlled trials have demonstrated the superiority of rituximab monotherapy compared with conventional immunosuppressive therapy in patients with HCV-CV in whom prior antiviral therapy failed to induce disease remission 10, 11 . Rituximab was effective in 71.4% to 83% of patients with CV 10, 11 . However, in the absence of HCV clearance, frequent relapses occurred when B cells reemerged in the peripheral blood. Direct-acting antivirals (DAA) have proven to be very effective in patients with HCV-CV. A complete clinical response was achieved in 87.5% of HCV-CV patients treated with sofosbuvir plus ribavirin, and was closely correlated with virological response [12] [13] [14] . We previously reported a quantitative defect in regulatory T cells (Tregs) and clonal expansion of CD27 + IgM + CD21 -/low memory B cells in patients with HCV-CV [15] [16] [17] . It has been demonstrated that antiviral treatment can lead to the disappearance of symptoms and can induce an immunologic response, i.e., a significant decrease in plasma cryoglobulin levels and increase in Tregs 15, 18 . In addition, a decrease in B lymphocyte stimulator receptor 3 (BR3) staining on B cells was associated with an increase in serum M A N U S C R I P T
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B cell activating factor of the tumor necrosis factor family (BAFF) after rituximab in HCV-CV 19 .
However, little evidence is available about immunologic dynamics after IFN free DAA-based therapy. As a first examination of the immunologic effects of DAAs in HCV-CV, we evaluated both B and T cell subsets in patients at baseline (W0) and after DAA therapy at end of treatment (EOT) and post treatment (PT). Our results indicate that in addition to their virological effect, DAA-based therapy effectively normalize many of the disturbances in peripheral B-and T-lymphocytes homeostasis.
METHODS
Study population
Twenty-seven consecutive patients with HCV-CV (median age 59 years [range 53-66]) were included in the study and received interferon-free DAA therapy. All were positive for HCV RNA. The HCV viral load was quantified using the Abbott HCV RealTime assay (Abbott, Rungis, France), with a lower limit of detection of 12 IU/mL. To be eligible, the patient must have been at least 18 years of age or older (without any upper age limit), been informed of the study, and presented with active HCV vasculitis defined by clinically active vasculitis with skin, joint, renal, peripheral nerve, central neurological, digestive, pulmonary and/or cardiac involvement (no histological evidence needed if patient had purpura), and chronic active HCV infection (positive HCV RNA). Exclusion criteria included non-active cryoglobulinemia vasculitis, HIV or active HBV infection, and current decompensated cirrhosis.
Cryoglobulins were measured and classified as previously described 20, 21 . Twelve 
Antigen-specific stimulation with virus-like particles (VLPs)
PBMCs from HCV-CV patients were stimulated during 48 hours with peptide pools (15-mers overlapping by 10 amino acids; Eurogentec) spanning the whole sequence of the H77 strains E1 and E2, as previously described 22 . During the last 4 hours, brefeldin A was added. Tfh, Th1 and Th17 were identified by flow cytometry as previously described.
Data analysis and statistics
Analyses were performed using GraphPad Prism 6.0 software (Graph-Pad Software, San Diego, CA 
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RESULTS
Main characteristics of HCV-CV patients.
Patient characteristics are detailed in Table 1 
Abnormalities in peripheral cell homeostasis of HCV-CV.
Compared with healthy donors (HD) and HCV controls, pre-treatment abnormalities in HCV-CV patients included a decreased percentage of CD4 + CD25 hi FoxP3 + regulatory T cells (1.5% ± 0.2% versus 3.7% ± 0.2% for HD, P < .01, and versus 2% ± 0.4% for HCV controls, P = .6) ( Figure 1A, 1B) . We also found increases in: IgM + CD21 -/low memory B cells (35.7% ± 6.2% versus 7% ± 1.2% for HD, P = .0004, and versus 23.1% ± 4.6% for HCV controls, P = .23) ( Figure 1C, 1D for HD, P = .0001, and versus 6% ± 1.6% for HCV controls, P = .003) (Figure 2) .
We have evaluated the effect of antiviral therapy in PBMCs of HCV-CV patients after antigen-dependent stimulation by VLPs. We observed an expansion in Tfh, Th1 and Th17 at baseline (W0) that decreased after antiviral therapy (EOT and PT) (Suppl Figure 1) . HCV-CV versus 14% ± 2.5% for HD, P = .37, and 15.2% ± 3.4% for HCV controls, P = .75), and plasmablasts (2.3% ± 0.39% in HCV-CV versus 1% ± 0.19% for HD, P = .09, and 1.7% ± 0.44% for HCV controls, P = .59) (data not shown). 
Correlation between IgM
DAA-based therapy did not impact T-and B cells homeostasis in HCV patients without cryglobulinemia (Suppl Figure 2).
Serum levels of IFNγ, IL12 p70, IL17A and IL21 decreased significantly in HCV-CV patients after DAA therapy (26 ± 4.6 versus 22.9 ± 4.7 pg/ml; 13.1 ± 2.4 versus 11.5 ± 3.2 pg/ml; 20.7 ± 7.1 versus 19.8 ± 7.9 pg/ml; and 20.4 ± 7.6 versus 17.3 ± 6.9 pg/ml, respectively, P < .05) ( Table 2 ). Serum levels of TNFα, IL-4, IL-5, IL-10 and IL-13 did not differ significantly before and after DAA therapy. We did not observed significant
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Serum levels of BAFF tended to decrease after DAA therapy but did not reach statistical significance (1898 ± 371 versus 1491 ± 194 pg/ml, P = .58).
BR3 and PD-L1 expression on B cells are modulated by DAA therapy, and expression of BR3 was negatively correlated with BAFF in serum.
BR3 staining levels on B cells were increased in HCV-CV patients when compared before and after DAA therapy (MFI 37 ± 2.4 versus 47 ± 2.6, P < .01) ( Figure   5A , 5B). Similarly, PD-L1 staining levels on B cells were increased in HCV-CV patients when compared before and after DAA therapy (MFI 29 ± 7.3 versus 48 ± 9.3, P < .05) ( Figure 5C, 5D) . MFI of BR3 was negatively correlated with BAFF in serum (r = ─ 0.46, P = .039) ( Figure 5E ).
We analyzed PD-1 and CTLA-4 expression on Tregs before and after DAA-based therapy. We did not observed difference relative to PD-1 expression (MFI 1.9 ± 0.7 at W0 versus 1.7 ± 0.5 at EOT), but an increase in CTLA-4 expression (MFI 9.3 ± 2.6 at W0 versus 11.7 ± 3.8 at EOT) after DAA-based therapy.
DISCUSSION
Mixed cryoglobulinemia vasculitis is a serious autoimmune condition, which is predominantly induced by chronic HCV infection. It is an example of infection-associated tolerance failure, which leads to an immune response directed against host tissues. As and Th17 (IL-17A) cytokine serum levels was observed.
We previously showed that the use of low-dose interleukin-2 leads to regulatory T 47, 48 . BAFF is also involved in the regulation of Tfh cells.
BAFF directly stimulates T-cell proliferation and cytokine production 49 .
In the present study, BR3 and PD-L1 expressions on B cells increased after DAA therapy. This is in sharp contrast with the results found after rituximab treatment, i.e. a marked increase in serum BAFF concentration and decrease in BR3 staining, a factor which may indicate an increase in BAFF receptor-ligand activity 19 . It may be hypothesized that repopulation of the B cell compartment in a BAFF-rich environment favors autoreactive clones, which may be of special importance in HCV-induced B cell proliferative disorders. Along this line, it has recently been shown that rituximab does not reset defective early B cell tolerance checkpoints 50 . Taken together, these results indicate that BAFF receptor-ligand system normalization is a characteristic of remission induced by IFN free DAA-based therapy.
In conclusion, our study identified Tfh expansion associated with Th1 and Th17 
